Exicon Co., Ltd. — Major Shareholding Notification 2016

Jan 25, 2016

Copenhagen, 2016-01-25 18:16 CET (GLOBE NEWSWIRE) -- Exiqon A/S, listed on
Nasdaq Copenhagen (“EXQ”), has been informed that Danske Invest (CVR-nr.
15161582) with address at Parallelvej 17, 2800 Kgs. Lyngby, Denmark, after sale
of shares owns less than 5% of the share capital and voting rights in Exiqon
A/S.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We
empower scientists across the world with best-in-class products and
user-friendly business solutions designed to transform workflows in our
industry. Exiqon operates in two business areas: Exiqon Life Sciences is a
leading provider of flexible solutions for gene expression analysis. Academia,
biotech and pharmaceutical companies around the world use Exiqon’s research
products to make ground-breaking discoveries. Exiqon Diagnostics collaborates
with diagnostic and pharmaceutical companies to develop novel molecular
diagnostic tests for early detection of diseases, which can help physicians
make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For
more information about us, please visit www.exiqon.com